Selected article for: "antibiotic treatment and pneumococcal pneumonia"

Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial
  • Document date: 2019_5_18
  • ID: 19ueli6e_3
    Snippet: Although animal models suggest a beneficial effect of rifamycins in the reduction of inflammation during pneumococcal infections, 13 data in humans are not available. Therefore, we hypothesized that non-lytic rifampicin compared with lytic b-lactam antibiotic treatment would attenuate the inflammatory response in patients with pneumococcal pneumonia, shortly after the start of their treatment......
    Document: Although animal models suggest a beneficial effect of rifamycins in the reduction of inflammation during pneumococcal infections, 13 data in humans are not available. Therefore, we hypothesized that non-lytic rifampicin compared with lytic b-lactam antibiotic treatment would attenuate the inflammatory response in patients with pneumococcal pneumonia, shortly after the start of their treatment.

    Search related documents:
    Co phrase search for related documents
    • animal model and beneficial effect: 1, 2, 3
    • animal model and inflammation reduction: 1
    • animal model and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibiotic treatment and beneficial effect: 1, 2
    • antibiotic treatment and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • antibiotic treatment and non lytic rifampicin: 1, 2, 3
    • antibiotic treatment and pneumococcal infection: 1, 2, 3, 4, 5
    • antibiotic treatment and pneumococcal pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • antibiotic treatment and treatment start: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • beneficial effect and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • beneficial effect and treatment start: 1, 2, 3
    • inflammation reduction and pneumococcal infection: 1
    • inflammatory response and non lytic rifampicin: 1, 2, 3, 4
    • inflammatory response and pneumococcal infection: 1, 2, 3, 4
    • inflammatory response and pneumococcal pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • inflammatory response and treatment start: 1, 2, 3, 4, 5
    • non lytic rifampicin and pneumococcal infection: 1
    • non lytic rifampicin and pneumococcal pneumonia: 1, 2, 3
    • pneumococcal infection and treatment start: 1